

DRUG DISCOVERY & DEVELOPMENT VIRTUAL EVENT SERIES

FEBRUARY 23, 2022



Date	Time	Track	Presentation Title	Speaker
23-Feb	06:00 - 07:00 AM	Advancements in Clinical Development	Autoantibodies as Biomarkers in Immunoncology	Hans-Dieter Zucht, PhD Chief Technical Officer, Oncimmune Germany GmbH
23-Feb	07:30 - 08:30 AM	Novel Approaches to Drug Discovery and Preclinical Development	Keynote Presentation: Profiling of Receptor Complexes using BRET	Professor Kevin Pfleger, MA, PhD, FBPhS Director, Biomedical and Health Innovation, The University of Western Australia and WA Life Sciences Innovation Hub; President, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT); Head, Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research (Centre for Medical Research, The University of Western Australia); Deputy Director & UWA Node Leader, ARC Centre for Personalised Therapeutics Technologies
23-Feb	09:00 - 10:00 AM	Advancements in Clinical Development	Keynote Presentation: Engineering the Quantum Leap that Drug Development Needs	Michelle Longmire, MD CEO & Co-founder, Medable
23-Feb	10:30 - 11:30 AM	Novel Approaches to Drug Discovery and Preclinical Development	Standardized and Reproducible Solutions for Flow Cytometry Analytics	Emily Bozek, MSc Product Manager
23-Feb	12:00 - 01:00 PM	Advancements in Clinical Development	Panel Presentation: Digital Solutions to Alleviate NASH Clinical Trial Challenges	Paul McCracken, PhD Vice President, Global Head of Medical Imaging, ICON Debbie Marshall Program Manager, ICON Christina Gonzalez Project Manager, Pathology, ICON
23-Feb	01:30 - 02:30 PM	Novel Approaches to Drug Discovery and Preclinical Development	Human-Certified 'omics Data to Power Drug Discovery	Joseph Pearson, PhD Global Product Manager, QIAGEN Digital Insights

23-Feb	01:30 - 02:30 PM	Advancements in Clinical Development	Innovative Approaches to Biomarker Discovery in the Drug Development Process	Esperanza Anguiano, PhD, MS-MBA Scientific Market Development Director of BioPharma, Nanostring
23-Feb	03:00 - 04:00 PM	Novel Approaches to Drug Discovery and Preclinical Development	Genetically Engineered Custom Cell Lines for Pre-Clinical Research and Biomanufacturing	Stacey Ward, PhD R&D Manager, Advanced Genetic and Cell Technologies, MilliporeSigma
23-Feb	11:55 - 11:55 PM	Novel Approaches to Drug Discovery and Preclinical Development	Addressing Both Sides of the Coin - Microphysiological Systems to Better Predict Safety and Efficacy of Novel Therapies	Audrey Dubourg, MSc, PhD Product Manager OOC, CN-Bio
23-Feb	11:55 - 11:55 PM	Explorations into PK/PD and Pharmacogenomics	Development and Characterization of an In Vitro Integrated Organ Platform for the Evaluation of Pharmacokinetic and Toxicologic Effects of Drugs and Chemicals	James McKim, PhD President and CEO, IONTOX
23-Feb	11:55 - 11:55 PM	Advancements in Clinical Development	Enabling Translation of Biomarker Research to Clinical Practice	Fergus Fleming Co-Founder, Executive Director, Chief Technical Officer, Renalytix PLC
23-Feb	11:55 - 11:55 PM	Novel Approaches to Drug Discovery and Preclinical Development	How to Wake a Giant - Concepts of Adhesion GPCR Activation and their Potential Therapeutic Implications	Ines Liebscher, PhD Professor, Leipzig University, Rudolf-Schönheimer-Institute of Biochemistry
23-Feb	11:55 - 11:55 PM	Advancements in Clinical Development	Identification of Novel Protein Biomarkers in the Era of Precision Medicine Oncology	Hilal Arnouk, MD, PhD Associate Professor, Dept. of Pathology, Midwestern University
23-Feb	11:55 - 11:55 PM	Novel Approaches to Drug Discovery and Preclinical Development	Identifying the Ideal In Vitro Liver Model for Various Research Applications	Michael Johnson, PhD President, New Jersey Innovation Institute
23-Feb	11:55 - 11:55 PM	Novel Approaches to Drug Discovery and Preclinical Development	Next Generation Biobanking of Patient-derived Organoid Models	Nikolina Radulovich, PhD Staff Scientist, Princess Margaret Hospital in Toronto

23-Feb	11:55 - 11:55 PM	Explorations into PK/PD and Pharmacogenomics	Personalised Medicine Through GPCR Pharmacogenomics	Alexander Sebastian Hauser, PhD Assistant Professor, Department of Drug Design and Pharmacology, University of Copenhagen
--------	---------------------------	--	---	---